Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis.

Nutr Metab Cardiovasc DisJun 24, 2026 (epub)
Clinical ResearchCardiology

Sining Xie, Federica Galimberti, Elena Olmastroni et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the safety of lipid-lowering therapies (LLTs) in 303,397 adults. It found that PCSK9 monoclonal antibodies (PCSK9mAbs) had a lower risk of creatine kinase elevation, diabetes, and liver dysfunction compared to statins, with relative risks of 1.44, 1.13, and 1.38, respectively. Bempedoic acid was associated with the lowest risk of myalgia.

Key findings

  • Bempedoic acid had the lowest risk of myalgia compared to PCSK9mAbs (RR 0.80 [0.69, 0.93]).
  • PCSK9mAbs showed a lower incidence of creatine kinase elevation compared to statins (RR 1.44 [1.14, 1.81]).
  • PCSK9mAbs were associated with a lower risk of diabetes compared to statins (RR 1.13 [1.05, 1.22]).
  • PCSK9mAbs had a lower risk of liver dysfunction compared to statins (RR 1.38 [1.17, 1.62]).

Why it matters

Understanding the comparative safety profiles of lipid-lowering therapies is crucial for clinicians to make informed decisions, particularly for patients at higher risk of adverse events. This analysis provides valuable insights for tailoring treatment strategies.

Source

PubMed · PMID 42386462

Published in Nutr Metab Cardiovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.